ArticleCancer research2013
scFv-based "Grababody" as a general strategy to improve recruitment of immune effector cells to antibody-targeted tumors.
Article in Cancer research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- HED, a Human-Engineered Domain, Confers a Unique Fc-Binding Activity to Produce a New Class of Humanized Antibody-like Molecules.International journal of molecular sciences · 2023Article
- Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era.Breast (Edinburgh, Scotland) · 2021Review
- Rational Design of Constrained Peptides as Protein Interface Inhibitors.Antibodies (Basel, Switzerland) · 2021Review
- Universal endogenous antibody recruiting nanobodies capable of triggering immune effectors for targeted cancer immunotherapy.Chemical science · 2021Article
- Clinical development of immunotherapies for HER2NPJ breast cancer · 2020Review
- Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.Journal of hematology & oncology · 2019Review
- Interference-Free HER2 ECD as a Serum Biomarker in Breast Cancer.Journal of molecular biomarkers & diagnosis · 2014Article
- Facile method for the site-specific, covalent attachment of full-length IgG onto nanoparticles.Small (Weinheim an der Bergstrasse, Germany) · 2014Article
- Lysosome-dependent p300/FOXP3 degradation and limits Treg cell functions and enhances targeted therapy against cancers.Experimental and molecular pathology · 2013Article
- Empowering scFv with effector cell functions for improved anticancer therapeutics.Oncoimmunology · 2013Article
- A targeted immunotherapy approach for HER2/neu transformed tumors by coupling an engineered effector domain with interferon-γ.OncoimmunologyArticle
- Therapeutic potential of an anti-HER2 single chain antibody-DM1 conjugates for the treatment of HER2-positive cancer.Signal transduction and targeted therapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Recruitment of immune cells to tumor cells targeted by a therapeutic antibody can heighten the antitumor efficacy of the antibody. For example, p185(her2/neu)-targeting antibodies not only downregulate the p185(her2/neu) kinase (ERBB2) but also trigger complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the antibody Fc region. Here, we describe a generalized strategy to improve immune cell recruitment to targeted cancer cells, using a modified scFv antibody we call a "Grababody" that binds the target protein and endogenous immunoglobulins. The model system we used to illustrate the use of this platform recognizes p185(her2/neu) and includes an IgG binding domain. The recombinant scFv Grababody that was created recruited circulating human IgGs and attracted immune cells carrying Fc receptors to tumor cells that expressed p185(her2/neu). The presence of the IgG binding domain significantly enhanced CDC and ADCC activity and improved antitumor activity in vivo. Our results illustrate a novel general approach to improve antibody-like proteins for therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.